CognitiveLow Risk

Noopept

Also known as: N-phenylacetyl-L-prolylglycine ethyl ester, Omberacetam

Half-life:: ~15-30 minutes (active metabolite has longer CNS retention)

Administration Routes

oralsublingualintranasal

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Prodrug converting to cycloprolylglycine; modulates AMPA and NMDA receptors; increases NGF and BDNF expression

A synthetic dipeptide nootropic with potent cognitive-enhancing and neuroprotective effects. Much more potent than piracetam at lower doses.

Primary Research Areas

memory consolidation
learning enhancement
neuroprotection
BDNF increase

Risk Profile

Low Risk

Generally considered lower risk in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Russian cognitive enhancer (omberacetam). Prescription drug in Russia. NOT FDA-approved. Sold as nootropic supplement in US but does not qualify as dietary supplement under DSHEA. Unscheduled.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find Noopept

No active associated providers listed yet.